Robert H. Eibl, MD, is an independent medical scientist working in cancer research and biophysics. He received his medical doctorate from Heidelberg University, with doctoral research at the German Cancer Research Center (DKFZ) in molecular cell biology. He later conducted research at the University Hospital of Zürich, the Nuclear Research Center Karlsruhe, Stanford University, the Technical University of Munich, the Max Planck Institute for Polymer Research in Mainz, and the University of Miami. Following work on his SV40 large T antigen-induced brain tumor model, he identified the first TP53 mutations reported in primary human medulloblastoma tissue. TP53 mutation status later became part of the current WHO classification of medulloblastoma and has particular prognostic relevance in SHH-activated tumors. At Stanford University, he conducted independent research with Irving L. Weissman and Eugene C. Butcher on cell adhesion and metastatic dissemination. His research has covered tumor genetics, CD44 variants and metastasis, tumor-cell adhesion, atomic force microscopy, and single-molecule force spectroscopy. He has also written several reviews on circulating tumor cells and liquid biopsy. Recent studies include VLA-4/VCAM-1-mediated melanoma cell adhesion and single-molecule double-cell force spectroscopy (SM-DCFS). He is a member of Sigma Xi and has received several reviewer and publication awards and distinctions.
Sigma Xi
Sigma Xi, Durham, USA
The scientific research honor society
TOP 1000 reviewers
MDPI, Basel, Switzerland
Reviewer of the month
Translational Cancer Research, Hong Kong, China
Highly Cited Paper Award
Open Exploration, Xi’an, China
Best Paper of the Year
Open Exploration, Xi’an, China
Poster presentation award
German Cancer Research Center, Heidelberg, Germany
Poster award
1st Spring School on Immunology, Garmisch-Partenkirchen, Germany
Deans fellowship School of Medicine
Stanford University, Stanford, USA

Outstanding Reviewer Award
MDPI
Awarded by Cancers in 2025